Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look

Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies (ADPT +3.46%), reported the sale of 81,342 shares of common stock for a total consideration of approximately $1.21 million, as disclosed in a March 10, 2026 SEC Form 4 filing.Transaction summaryMetricValueShares traded (direct)81,342Transaction value$1.2 millionPost-transaction shares (direct)643,471Post-transaction value (direct ownership)~$9.34 millionTransaction value based on SEC Form 4 weighted average purchase price ($ ...